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Abstract
Background: We hypothesized that the contrast medium gadobutrol is not inferior compared to Gd-DTPA in
identifying and quantifying ischemic late gadolinium enhancement (LGE), even by using a lower dose.
Methods: We prospectively enrolled 30 patients with chronic myocardial infarction as visualized by LGE during
clinical routine scan at 1.5 T with 0.20 mmol/kg Gd-DTPA. Participants were randomized to either 0.15 mmol/kg
gadobutrol (group A) or 0.10 mmol/kg gadobutrol (group B). CMR protocol was identical in both exams.
LGE was quantified using a semiautomatic approach. Signal intensities of scar, remote myocardium, blood and air
were measured. Signal to noise (SNR) and contrast to noise ratios (CNR) were calculated.
Results: Signal intensities were not different between Gd-DTPA and gadobutrol in group A, whereas significant
differences were detected in group B. SNR of injured myocardium (53.5+/−21.4 vs. 30.1+/−10.4, p = 0.0001) and CNR
between injured and remote myocardium (50.3+/−20.3 vs. 27.3+/−9.3, p < 0.0001) were lower in gadobutrol. Infarct
size was lower in both gadobutrol groups compared to Gd-DTPA (group A: 16.8+/−10.2 g vs. 12.8+/−6.8 g, p = 0.03;
group B: 18.6+/−12.0 g vs. 14.0+/−9.9 g, p = 0.0016).
Conclusions: Taking application of 0.2 mmol/kg Gd-DTPA as the reference, the delineation of infarct scar was similar
with 0.15 mmol/kg gadobutrol, whereas the use 0.10 mmol/kg gadobutrol led to reduced tissue contrast.
Trial registration: The study had been registered under EudraCT Number: 2010-020775-22. Registration date:
2010.08.10
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Background
Myocardial infarction is a leading cause of mortality
worldwide. Accurate assessment of infarct size and
morphology is important for clinical decision making in
a lot of clinical settings [1, 2]. Currently, late gadolinium
enhancement cardiac magnetic resonance (LGE-CMR) is
a well-established and accurate method to assess scar
morphology [3] and is widely used in clinical CMR [4, 5].
Until now, Gd-DTPA, a linear ionic gadolinium chelate, is
the extracellular contrast agent that is mostly used for de-
tection of myocardial LGE and is commonly administered
as double dose (0.2 mmol/kg). After the administration of
Gd-DTPA, cases of nephrogenic systemic fibrosis (NSF)
in patients with renal failure have been reported, leading
to a new risk classification of contrast media [6]. Whereas
the detailed mechanism of NSF is not known, it could be
shown in animal experiments that the tissue gadolinium
distribution is altered in case of renal impairment [7].
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Gadobutrol is a macrocyclic nonionic gadolinium
chelate with a higher T1 relaxivity compared to Gd-
DTPA (gadobutrol: r1 = 4.7 mmol−1s−1; Gd-DTPA: r1 =
3.9 mmol−1s−1, at 1.5 Tesla, in human blood plasma, at
37 °C) [8]. The binding profile is known to be more
stable, thus through to have a lower risk of NSF. Only
three controversially discussed cases of NSF were re-
ported after the use of gadobutrol worldwide until now
[9, 10]. Therefore gadobutrol is classified as a low risk
contrast-medium. This and the higher relaxivity are
driving forces for further evaluations in cardiovascular
settings.
Today, there are only limited data available analyzing
the influence of contrast agents with different relaxivities
on LGE quantification. In this study, we hypothesized
that gadobutrol, which is characterized by a higher relax-
ivity compared to Gd-DTPA, is not inferior to Gd-
DTPA in identifying and quantifying ischemic LGE, even
when using a lower dose.
Methods
Patients’ enrollment
Between September 2010 and December 2011, pa-
tients with a history of a chronic myocardial infarc-
tion and LGE as assessed during a clinical CMR scan
using 0.20 mmol/kg Gd-DTPA were screened and
asked for participation in a second study-related CMR
scan. All included patients gave written informed con-
sent and were scheduled for a second CMR examin-
ation afterwards. The study had been registered under
EudraCT number: 2010-020775-22 and was accord-
ingly approved by the ethical board of the city of
Berlin (LAGESO).
The sample size of this randomized prospective trial
was calculated based on a power calculation. The as-
sumption was, that for a two-sided alpha of 5 % and a
power of 80 % based on a delta of 0.15, 15 patients per
dose gadobutrol have to be included.
Patients were randomized for either 0.15 mmol/kg
(group A) or 0.10 mmol/kg (group B) gadobutrol. All
patients were in normofrequent sinus rhythm.
Inclusion criteria
 between 18 and 80 years of age
 chronic myocardial infarction (>3 months old)
based on coronary artery disease (CAD), detected
by invasive angiography
 successfully performed clinical LGE CMR study
within the last 4 weeks
 evidence of single myocardial infarction on LGE
CMR with “hyper-enhancement” involving at least
two contiguous short-axis slices
 written informed consent
Exclusion criteria
 severe arrhythmia, atrial fibrillation
 history of moderate or severe impairment of renal
function (GFR < 60 ml/min)
 additional myocardial infarction or acute coronary
syndrome during the last 4 weeks
 general contraindications for CMR
Image acquisition
CMR was performed on a 1.5Tesla cardiac-dedicated clin-
ical MR system (Avanto, Siemens Healthcare, Erlangen,
Germany) using a 12-channel coil. Identical CMR proto-
cols were applied for both examinations.
LGE LGE was assessed in all patients starting 13 min
after contrast administration in a short axis stack by
using a 2D inversion recovery gradient echo sequence
(slice thickness 8 mm, no gap, TE 5.0 ms, FA 30°, matrix
256×192, field of view 350×262mm) with an inversion
time (TI) adjusted to null signal from normal myocar-
dium. In case of questionable bright signal in the myo-
cardium during the scan, we changed the read out or
acquired a perpendicular slice to exclude artefacts. Slice
position was identical as for cine imaging using a single
slice single breathold approach.
T1 quantification T1 quantification was performed with
a Modified Look-Locker Inversion-recovery (MOLLI) se-
quence [11], acquired in a mid-ventricular short-axis slice
before and 1, 3, 5, 9, 20 min after contrast administration.
Multiple post-contrast measurements were performed to
show the optimal time point of image acquisition after
contrast administration. Imaging parameters were: non-
selective inversion pulse, steady-state free precession
single-shot read out in mid-diastole, field of view 223 ×
320 mm, matrix 174 × 192, slice thickness 8 mm, TE
1.08 ms, FA 35°, bandwidth 1002Hz/Px, minimum inver-
sion time of 100 ms, maximum inversion time of
3600 ms.
Image analysis
Function For analyzing LV function and volumes, the
endocardial and epicardial contours were manually drawn
in systole and diastole using dedicated software (CMR42,
circle, Calgary, Canada). LV mass was calculated as total
myocardial volume multiplied by the specific gravity of
the myocardium (1.05 g/ml). LV mass and LV end dia-
stolic volume were indexed to height.
LGE The readers were blinded to the group assignment.
For quantification of LGE a semiautomatic gray-scale
threshold technique was performed as published previously
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[12]. Areas of LGE were defined as a signal intensity of
more than 6 standard deviations (SD) above the mean of
remote myocardium.
Signal intensities of scar tissue, remote myocardium,
blood and air were measured by drawing free-hand ROIs
of approximately 10–20 pixels in each LGE short axis
stack. Reproducible locations were achieved by using ana-
tomical landmarks in dedicated software (CMR42, circle
international, Calgary Canada). For signal-to-noise ratio
(SNR) and contrast-to-noise ratio (CNR) the following
sequations were used [13]:
SNR ¼ mean signal of ROI=standard deviation
of background noise: CNR ðbetween tissue A
and tissue BÞ ¼ SNR Að Þ–SNR Bð Þ:
T1 quantification T1 maps were constructed offline
using MRmap [14, 15] a customized software program writ-
ten in Interactive Data Language (IDL; RSI International,
Boulder, CO, USA). The position of the source images was
initially manually adjusted to correct for potential mis-
registration. A curve fit of the MOLLI source images
was then performed, with automatic calculation of T1
values for each pixel. A T1 parametric map was subse-
quently generated and used for further analysis. The
parametric maps were evaluated in CMR42. Freehand
ROI’s of approximately 10–20 pixels were placed in scar
tissue, remote myocardium and blood for measuring
the averaged T1 time in this tissue. Reference for scar
delineation was the LGE image in the same plane
(Fig. 1).
Interobserver variability
To test inter-observer variability in LGE quantification,
two readers who were blinded to each other’s results an-
alyzed all examinations.
Statistical analysis
Statistical analyses were performed using SAS 9.2 (SAS
Institute Inc., Cary, NC, USA) and SPSS 21.0 for win-
dows (Chicago, Il, USA). Data are presented as mean ±
standard deviation. Statistical tests were performed using
non-parametric methods due to the low sample size
within each group. Continuous data were compared
using the Wilcoxon rank sum tests. Paired data were
compared using Wilcoxon signed rank tests. Categorical
data were compared using Fisher's exact test. Statistical
tests were considered significant with the two-sided p <
0.05. Spearman correlation coefficient’s were used to de-
termine observer-related variability. Boxplots were gen-
erated with SPSS and show median (line in the middle),
1st quartile (bottom of box), 3rd quartile (top of box),
lowest case within 1.5 times IQR (bottom whisker),
highest case within 1.5 times IQR (top whisker) and
outliers.
Fig. 1 T1-Mapping. LGE-image in short axis view (left) with corresponding T1-map (center and right) show a transmural anteroseptal myocardial
infarction. ROIs (infarct region, remote myocardium and blood pool) were drawn on the map (right)
Table 1 Patient’s characteristics
Group A Group B
Male/female 15/0 15/0
Age (years) 70.20 ± 4.70 63.50 ± 10.70
Scar amount (g) 16.77 ± 10.18 18.63 ± 11.98
SNR scar 45.51 ± 22.56 53.45 ± 21.40
CNR between scar tissue
and remote myocardium
41.76 ± 21.24 50.27 ± 20.30






SNR of scar tissue 45.51 ± 22.56 47.04 ± 19.78 >0.9999
CNR between scar tissue
and remote myocardium
41.76 ± 21.24 42.83 ± 17.31 >0.9999
SNR of blood 43.97 ± 16.32 44.37 ± 16.20 0.6698
CNR between scar tissue
and blood
1.53 ± 17.18 2.65 ± 14.02 0.5153
Amount of LGE (g) 16.77 ± 10.18 12.84 ± 6.79 0.0300
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Results
We screened 252 patients and identified 51 who met our
criteria. 30 patients agreed to participate in the trial
and were prospectively enrolled in the study and ran-
domized to either 0.15 mmol/kg gadobutrol (group A)
or 0.10 mmol/kg gadobutrol (group B). 21 patients re-
fused participation due to a lack of motivation or fear
of repeated contrast administration. There were no sig-
nificant differences between groups relating age, scar
amount and signal intensities for control agent Gd-
DTPA (Table 1). The time duration between both scans
was at maximum 30 days. We took the history again to
check for clinical events. In none of the patients a clin-
ical event was existing.
No complications related to contrast administration
were observed. Infarcts were detectable in all patients.
Comparison of signal intensities and LGE amount
In group A signal intensities showed no differences be-
tween Gd-DTPA and gadobutrol (Table 2, Figs. 2 and 3).
Amount of LGE was lower in gadobutrol, the absolute
difference was small, but reached statistical significance
(p = 0.03).
In group B signal intensities showed significant dif-
ferences between Gd-DTPA and gadobutrol. In par-
ticular SNR of injured myocardium and CNR between
injured and remote myocardium were significantly
lower in gadobutrol resulting in a significant smaller
Fig. 2 LGE (short axis view) example images from group A. Left: after 0.2 mmol/kg BW Gd-DTPA. Right: after 0.15 mmol/kg BW gadobutrol
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Fig. 3 Boxplots showing SNR-, CNR and LGE amount in group A. Left: after 0.2 mmol/kg BW Gd-DTPA. Right: after 0.15 mmol/kg BW gadobutrol
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scar size as defined by the amount of LGE (Table 3,
Figs. 4 and 5).
Interobserver Variability of LGE quantification
Interobserver variability was low and without differences
between the contrast agents in both groups (Table 4).
T1 mapping
For technical reasons we were able to perform a pairwise
analysis in only six patients of group A. Interestingly, in
this subgroup we found no significant differences be-
tween both contrast media regarding T1 times of the dif-
ferent tissues at different time- points after contrast
administration (Table 5).
The drop-out rate was high due to two main-aspects:
I) The applied sequence was a first generation one as de-
scribed in the method section. II) The most frequent
limitation was the registration failure of the raw images
especially in regions of wall thinning respectively the in-
farct area.
Discussion
In the present study we compared the depiction of
chronic myocardial infarction using two different con-
trast media and different doses in a prospective random-
ized setting. The null hypothesis of our study was, that
the infarct volume with gadobutrol is not equivalent to
the infarct volume with the control agent. This was
confirmed by our results. The main results are the
following:
I) Scar was detectable with each contrast media and
dose. II) The use of 0.15 mmol/kg BW (body weight)
gadubutrol led to similar results compared to 0.2 mmol/
kg BW Gd-DTPA regarding signal intensity and contrast
whereas the application of 0.1 mmol/kg gadobutrol led
to a significant poorer delineation of scar tissue. III)
Both doses gadobutrol led to a smaller infarct size taking
0.2 mmol/kg BW Gd-DTPA as the reference. IV) Obser-
ver variability of LGE quantification was independent
from type and dose of contrast agent.
Although our sample size was small, but defined in a
random setting, we could confirm in part the data by
Durmus et al., who compared 0.15 mmol/kg BW gado-
butrol with 0.2 mmol/kg BW Gd-DTPA in 20 patients
with myocardial infarction [16]. They showed that gad-
obutrol led to similar infarct size and CNR between
scar and remote myocardium compared to Gd-DTPA.
In contrast to our results, CNR between scar and blood
even increased with gadobutrol in their study, whereas
we observed no significant difference in group A be-
tween gadubutrol and Gd-DTPA regarding SNR of
blood as well as CNR between scar and blood. Our
finding are supported by the quantitative parametric
T1-mapping results as presented in a subgroup.
DeCobelli et al. compared gadobutrol with Gd-DTPA
in patients with positive LGE regardless of its etiology
[17]. They showed that 0.1 mmol/kg BW gadobutrol is
as effective as 0.2 mmol/kg BW Gd-DTPA regarding sig-
nal intensities and quantification of injured tissue. Our
data (group B) are different to these results. In our study
0.1 mmol/kg BW gadobutrol led to poorer delineation of
infarct scar and reduced amount of LGE as found by
both readers. A possible explanation for this discrepancy
between both studies could be the different patient






SNR of scar tissue 53.45 ± 21.40 30.11 ± 10.36 0.0001
CNR between scar tissue
and remote myocardium
50.27 ± 20.30 27.32 ± 9.28 <0.0001
SNR of blood 48.57 ± 17.69 19.84 ± 6.33 <0.0001
CNR between scar tissue
and blood
4.89 ± 12.96 10.29 ± 9.26 0.0554
Amount of LGE (g) 18.63 ± 11.98 14.03 ± 9.92 0.0016
Fig. 4 LGE (short axis view) example images from group B.
Left: after 0.2 mmol/kg BW Gd-DTPA. Right: after 0.1 mmol/kg
BW gadobutrol
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Fig. 5 Boxplots showing SNR-, CNR and LGE amount in group B. Left: after 0.2 mmol/kg BW Gd-DTPA. Right: after 0.1 mmol/kg BW gadobutrol
Rudolph et al. BMC Medical Imaging  (2015) 15:55 Page 7 of 10
population. DeCobelli et al. evaluated heterogeneous
groups including non-ischemic heart-diseases. It is well-
known, that the quantification in this more diffuse fibro-
sis is on one hand more challenging due to the small
size and the blurred borders, but on the other hand the
location in non-ischemic disease is typically intramural.
That facilitates the differentiation from the bright blood
pool signal. The different character of the fibrotic tissue
in non-ischemic and ischemic heart disease seems to lead
to the application of different standard-deviation for scar-
sizing. In case of non-ischemic heart disease, often two
standard deviations were applied to differentiate LGE
from remote myocardium [18, 19]. For clinical deci-
sion making usually visual assessment of LGE images
is recommended, whereas quantitative analysis of LGE
extent and/or “grey-zone” extent is common for re-
search purposes [20]. The integration of pharmacoki-
netic models with different compartments could also
help to reduce the influence of different contrast dy-
namics in different types of fibrosis [21], as well as
different analysis tools [22].
One would assume that parametric mapping tech-
niques will help to overcome that problem. Whereas
mapping techniques are already applied in different dis-
eases and also for the quantification of extracellular vol-
umes [23, 24], no standardized approach is given today.
Furthermore automatic assessment of infarct borders will
help to overcome subjective approaches [25], but they also
depend on the predefined gold standards.
Independent of the quantification method itself, con-
trast media with higher relaxivity are warranted for po-
tential dose reduction. The concept of dose reduction in
contrast agents with higher relaxivity was also analyzed
for gadobenate dimeglumine. Recent studies have shown
a similar diagnostic performance and delineation of in-
farct scars using reduced doses of gadobenate dimeglu-
mine compared to standard dose Gd-DTPA (0.2 mmol/
kg BW) [26–28]. When comparing equivalent doses of
gadobenate dimeglumine with Gd-DTPA [29], higher
SNR- and CNR between scar and remote myocardium
was observed for gadobenate dimeglumine, whereas the
CNR between scar and blood decreased resulting in
poorer delineation of small subendocardial infarcts. New
technical developments could help to overcome this limit.
Recently, a new multi contrast LGE sequence (MCODE)
was proposed to improve detection of subendocardial
myocardial infarction [30].
Reduced dose of gadobutrol allows a reproducible de-
tection of myocardial infarction in all patients. In clin-
ical routine visual assessment of scar is accepted and
eye balling is accepted [12]. But scar quantification may
play an important role in treatment planning in future
and is expected to play a crucial role in risk stratification
[1, 31, 32]. Therefore, a simple and robust post-processing
method is required. The present study demonstrated
that the inter-observer variability of LGE quantification
by using the 6-SD threshold yielded satisfactory results
in ischemic lesions independent from the contrast type
and dose. However, we observed that relaxivity and
dose influence the absolute results, which underlines
that accurate follow-up evaluations need constant CMR
conditions in clinical trials. CMR offers the unique cap-
ability to bring reliable (semi)quantitative approaches of
myocardial tissue differentiation based on contrast- and
non-contrast enhanced techniques into clinical routine
therefore standardization is of importance.
Table 4 Spearman’s correlation coefficients between the two
readers
Gd-DTPA Gadobutrol
Group A 0.85 0.93
Group B 0.91 0.94









myocardium 909 ± 199 990 ± 117 0.17
scar 1033 ± 226 978 ± 98 0.92
blood 1407 ± 42 1402 ± 62 0.53
1 min
myocardium 248 ± 38 250 ± 36 0.92
scar 207 ± 28 210 ± 36 0.75
blood 134 ± 18 144 ± 15 0.35
3 min
myocardium 305 ± 50 311 ± 23 0.75
scar 227 ± 18 241 ± 36 0.35
blood 181 ± 23 200 ± 17 0.25
5 min
myocardium 361 ± 57 360 ± 18 0.92
scar 275 ± 31 285 ± 48 0.46
blood 215 ± 21 248 ± 52 0.08
9 min
myocardium 416 ± 61 405 ± 22 0.6
scar 300 ± 50 308 ± 47 0.35
blood 260 ± 28 265 ± 21 0.6
20 min
myocardium 472 ± 63 468 ± 35 0.89
scar 351 ± 67 361 ± 64 0.5
blood 330 ± 42 337 ± 26 0.5
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Limitations
The present study was conducted at a single center with
a relatively small sample size. The study only included
men to omit the influence of sex on the results. Further
studies in women are necessary to extend the conclu-
sions to both sexes.
SNR- and CNR of LGE images are influenced by inver-
sion time. Its adjustment is operator-dependent. T1-
mapping was expected to add information on contrast-
media timing, but for technical reasons we were only
able to complete a pairwise T1 analysis in six patients of
group A. Larger studies preferably with mapping tech-
niques are needed to confirm our results.
Conclusions
The use of 0.15 mmol/kg BW gadobutrol led to compar-
able results as 0.20 mmol/kg BW Gd-DTPA in delinea-
tion of myocardial infarction and only to a small,
clinically non-relevant deviation in quantification of in-
farct scar and may be an appropriate alternative under
consideration of the lower risk for NSF. In contrast, the
dose of 0.10 mmol/kg BW gadobutrol was associated
with lower signal intensity and higher discrepancy re-
garding infarct size. Our results underline that accurate
scar evaluation during follow-up depends on type of
contrast agent and contrast dose and therefore requires
constant study conditions.
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